Artivion, Inc. AORT

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

What a brutal six months it’s been for Artivion. The stock has dropped 29.1% and now trades at $25.57, rattling many shareholders. This may have investors wondering how to approach the situation.

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

Artivion stock has delivered a 57.6% gain over the past three years, yet current valuation checks suggest the shares now sit close to their estimated intrinsic value, rather than offering a clear discount. With the Discounted Cash Flow (DCF) estimate and market multiples both pointing to pricing that looks broadly in line with fundamentals, the stock no longer looks obviously cheap or obviously expensive. Artivion is up 57.6% over three years. This means anyone looking at the stock today is...

Artivion (AORT) has drawn fresh attention after recent share price swings, with the stock up 3.1% in the latest session but still down 38.8% year to date as of 27 August 2026. Artivion’s recent 1 day share price return of 3.11% comes after a 7 day share price decline of 5.62%, with the stock still showing a year to date share price loss of 38.82%. The 3 year total shareholder return is 55.25%, suggesting longer term holders have seen a very different experience to recent buyers. Balance...

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.

Shares of medical device company Artivion (NYSE:AORT) jumped 2.5% in the afternoon session after Canaccord Genuity raised its price target on the stock to $40 from $39 while maintaining a Buy rating.

Artivion’s second quarter results were well received by the market, with performance driven by accelerating growth in its stent graft and On-X heart valve portfolios. Management credited strong On-X adoption, improved stent graft set sales, and a return to growth across international markets as key drivers behind the positive momentum. CEO Pat Mackin highlighted the recent FDA approval of the AMDS hybrid prosthesis and the acquisition of Endospan’s NEXUS system as important milestones, noting, “

Medical device company Artivion (NYSE:AORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.3% year on year to $125.8 million. The company expects the full year’s revenue to be around $488 million, close to analysts’ estimates. Its non-GAAP profit of $0.13 per share was 34.5% above analysts’ consensus estimates.

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]

Artivion Inc (AORT) reports 9% constant currency revenue growth in Q2 2026, fueled by strong stent graft and ONIX performance, while navigating integration costs and maintaining full-year guidance.

Medical device company Artivion (NYSE:AORT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.3% year on year to $125.8 million. The company expects the full year’s revenue to be around $488 million, close to analysts’ estimates. Its non-GAAP profit of $0.13 per share was 34.5% above analysts’ consensus estimates.

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.